Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now? The Motley Fool
Covered in this story
What has happened since
- Pfizer is up 0.0% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Pfizer
- Bank of America: at $28.3 · target $29 by Oct 2027 · Neutral via TIKR.com
- Cantor Fitzgerald: at $28.3 · target $28 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: at $28.3 · target $30 by Oct 2027 · Neutral via The Globe and Mail
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 46 stories mentioning Pfizer, the earliest published 2 Mar 2026.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.